Clemens Painsi1,2, Michael Patscheider2, Martin Inzinger1,3, Bernhard Lange-Asschenfeldt2, Franz Quehenberger4, Peter Wolf1. 1. Department of Dermatology, Medical University of Graz, Graz, Austria. 2. Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria. 3. Department of Internal Medicine, Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria. 4. Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
Abstract
BACKGROUND: Evidence of the efficacy of dithranol and patient perspectives on the treatment is scant. PATIENTS AND METHODS: Using a telephone interview survey, we collected retrospective data from 63 patients (41 men [65.1 %] and 22 women [34.9 %]) who had been treated with classic inpatient dithranol (CID). PsoRA (www.psoriasisregistry.at) was used to obtain clinical data and treatment responses, which were then correlated with the interview responses. RESULTS: Fifty-two (82.5 %) patients achieved a PASI75 and 51 (81 %) a PASI90 response within a median of 12.5 (range: 3 to 25) days. Ten out of twelve (83 %) patients showed a satisfactory response to CID (PASI75 or greater reduction) despite the fact that they had previously failed to adequately respond to methotrexate, oral retinoids, cyclosporine, or ustekinumab. Overall, patients recalled a median recurrence-free interval of four (95 % CI: 3-9) months after responding to CID, which was positively correlated with the patients' recommendation of (p = 0.018) and their overall high satisfaction with the treatment (p = 0.012). CONCLUSIONS: Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. CID can be effective in patients who have failed to respond to systemic therapy, including traditional agents and biologics.
BACKGROUND: Evidence of the efficacy of dithranol and patient perspectives on the treatment is scant. PATIENTS AND METHODS: Using a telephone interview survey, we collected retrospective data from 63 patients (41 men [65.1 %] and 22 women [34.9 %]) who had been treated with classic inpatient dithranol (CID). PsoRA (www.psoriasisregistry.at) was used to obtain clinical data and treatment responses, which were then correlated with the interview responses. RESULTS: Fifty-two (82.5 %) patients achieved a PASI75 and 51 (81 %) a PASI90 response within a median of 12.5 (range: 3 to 25) days. Ten out of twelve (83 %) patients showed a satisfactory response to CID (PASI75 or greater reduction) despite the fact that they had previously failed to adequately respond to methotrexate, oral retinoids, cyclosporine, or ustekinumab. Overall, patients recalled a median recurrence-free interval of four (95 % CI: 3-9) months after responding to CID, which was positively correlated with the patients' recommendation of (p = 0.018) and their overall high satisfaction with the treatment (p = 0.012). CONCLUSIONS: Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. CID can be effective in patients who have failed to respond to systemic therapy, including traditional agents and biologics.
Authors: Theresa Benezeder; Clemens Painsi; VijayKumar Patra; Saptaswa Dey; Martin Holcmann; Bernhard Lange-Asschenfeldt; Maria Sibilia; Peter Wolf Journal: Elife Date: 2020-06-02 Impact factor: 8.140
Authors: F M Bruins; I M G J Bronckers; R Cai; J M M Groenewoud; M Krol; E M G J de Jong; M M B Seyger Journal: Br J Dermatol Date: 2020-07-29 Impact factor: 9.302